Low-Dose Abiraterone With Low-Fat Meals: Non-Inferior to Standard Dose

Share this content:
Patients in both treatment arms had a PFS of about 9 months.
Patients in both treatment arms had a PFS of about 9 months.

Low-dose abiraterone acetate (AA) taken with a low-fat breakfast is non-inferior to standard-dose AA while fasting among patients with castration-resistant prostate cancer (CRPC), according to a study published in the Journal of Clinical Oncology.1

Studies leading to the approval of AA for CRPC were conducted among patients in a fasting state and may have established the standard dose at a much higher dose than necessary. For this open-label phase 2 study, researchers randomly assigned 72 patients with progressive CRPC to receive low-dose AA 250 mg with a low-fat meal or standard AA 1000 mg while fasting. All patients received prednisone 5 mg twice daily.

Prostate-specific antigen (PSA) levels were measured once per month. Serum testosterone and dehydroepiandrosterone sulfate (DHEA-S) levels were assessed every 3 months along with a radiographic imaging to assess disease burden.

After 12 weeks, patients treated with low-dose AA had a mean log change in PSA levels of -1.59 vs -1.19 among patients treated with standard-dose AA, establishing non-inferiority. The PSA response rate was 58% vs 50% in the low-dose vs standard-dose group, respectively.

Patients in both treatment arms had a progression-free survival (PFS) of about 9 months. AA concentration levels were, however, higher among patients treated with the standard dose.

AA is the most widely prescribed first-line agent for CRPC and is currently acquired wholesale at nearly $10,000 a month. With these median PFS estimates, switching to a low-dose AA regimen might save patients nearly $300,000.

The authors concluded that “given the pharmacoeconomic implications, these data warrant consideration by prescribers, payers, and patients. Additional studies are indicated to assess the long-term efficacy of this approach.”


  1. Szmulewitz RZ, Peer CJ, Ibraheem A, et al. Prospective international randomized phase II study of low-dose abiraterone with food versus standard dose abiraterone in castration-resistant prostate cancer. J Clin Oncol. 2018 Mar 28. doi: 10.1200/JCO.2017.76.4381

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs